Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Molecular Cytogenetics|November 1, 2018
Rare gene fusion rearrangement SPTNB1-PDGFRB in an atypical myeloproliferative neoplasmVanessa Fiorini Furtado, Neeraj Y Saini, William Walsh, et al.
JOP : Journal of the Pancreas|March 13, 2012
First-line treatment of metastatic pancreatic cancerMohammed Tokh, Venu Bathini, Muhammad Wasif Saif
Drugs & Aging|November 28, 2018
Novel Cancer Therapeutics in Geriatrics: What is Unique to the Aging Patient?Zeina Al-Mansour, Linda Pang, Venu Bathini
Clinical Breast Cancer|July 7, 2011
Effective role of hormonal therapy in metastatic primary neuroendocrine breast carcinomaAmanpreet Buttar, Kriti Mittal, Ashraf Khan, et al.
American Journal of Cancer Research|April 1, 2021
Utility of HNF-1B and a panel of lineage-specific biomarkers to optimize the diagnosis of pancreatic ductal adenocarcinomaShi Bai, James Lindberg, Giles Whalen, et al.
Frontiers in Oncology|September 28, 2020
Chimeric Antigen Receptor T-Cells in B-Acute Lymphoblastic Leukemia: State of the Art and Future DirectionsUri Greenbaum, Kris Michael Mahadeo, Partow Kebriaei, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 27, 2012
Phase-I/II study of bortezomib in combination with carboplatin and bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancerBilal Piperdi, William V Walsh, Kendra Bradley, et al.
Human Pathology|November 21, 2018
Heterogeneous mutational profile and prognosis conferred by TP53 mutations in appendiceal mucinous neoplasmsXiaoqin Zhu, Mohammed Salhab, Keith Tomaszewicz, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 23, 2021
Molecular and immunophenotypic characterization of anal squamous cell carcinoma reveals distinct clinicopathologic groups associated with HPV and TP53 mutation statusXiaoqin Zhu, Sarah Jamshed, Jian Zou, et al.
American Journal of Hematology|November 13, 2018
Elderly do benefit from induction chemotherapy: High dose mitoxantrone-based ("5 + 1") induction chemotherapy regimen in newly diagnosed acute myeloid leukemiaNeeraj Y Saini, Jan Cerny, Vanessa F Furtado, et al.
Pageof 3